GRAIL, Inc.

# GRAIL, Inc.

GRAIL operates as a commercial-stage diagnostics company focused on multi-cancer early detection. The company's primary product is Galleri, a blood-based screening test designed for asymptomatic individuals over 50 years of age to detect multiple cancer types at early stages. GRAIL also offers DAC (Diagnostic Aid for Cancer), which supports clinical decision-making for patients with suspected cancer by accelerating diagnostic resolution. Additionally, the company provides development services supporting clinical studies, pilot testing, and research programs, alongside work on minimal residual disease testing intended for post-diagnostic monitoring.

The company's revenue model centers on its screening and diagnostic testing services, though detailed segment breakdowns are not publicly specified. GRAIL maintains operations across the United States and internationally, with headquarters in Menlo Park, California. The company was incorporated in Delaware in 2015 and is publicly traded on Nasdaq with a market capitalization of approximately $2.3 billion. Specific employee count and revenue figures are not disclosed in available data.